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Polysorbate-80A revised broth microdilution susceptibility testing method for telavancin was approved by the Food and Drug
Administration (FDA). Telavancin activity was assessed against Gram-positive pathogens collected worldwide
(2013) using the revisedmethod. A total of 12,346 isolates from 90 sites were included as part of the Telavancin
International Surveillance Program for the Americas, Europe, and Asia-Paciﬁc. Telavancin had MIC50 and MIC90
values of 0.03 and 0.06 μg/mL, respectively, against staphylococci, regardless of methicillin susceptibility, and
inhibited all Staphylococcus aureus at≤0.12 μg/mL (revised FDA breakpoint). Telavancin was 8-fold more active
thandaptomycin (MIC50/90, 0.25/0.5 μg/mL) and 16- to 32-foldmore active than vancomycin (MIC50/90, 1/1 μg/mL)
and linezolid (MIC50/90, 1/1 μg/mL) against methicillin-resistant S. aureus. All 692 vancomycin-susceptible Entero-
coccus faecaliswere inhibited by telavancin (MIC50/90, 0.12/0.12 μg/mL) at≤0.25 μg/mL (FDA breakpoint), except
for 1 strain (MIC, 0.5 μg/mL). All Enterococcus faecium and E. faecalis with telavancin MIC values of ≥0.5 and
≥1 μg/mL, respectively, had a VanA phenotype. A comparison data analysis based on the MIC90 demonstrated
that telavancin was at least 8-fold more potent than comparators against vancomycin-susceptible enterococci.
Streptococci showed telavancin MIC50 values of ≤0.015 μg/mL, except for Streptococcus agalactiae (MIC50,
0.03 μg/mL). These in vitro results obtained by the recently approved susceptibility testing method establish a
new benchmark of telavancin activity worldwide.ax: +
ende
. Thi© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Telavancin is approved in theUnited States for the treatment of adults
with complicated skin and skin structure infections (cSSSIs) andhospital-
acquired (HABP) and ventilator-associated bacterial pneumonia (VABP)
caused by susceptible isolates of Staphylococcus aureuswhen alternative
treatments are not suitable (Theravance Biopharma Antibiotics, Inc,
2014). Telavancin is also approved in Canada for the treatment of cSSSI
caused by S. aureus, including methicillin-susceptible (MSSA) and
methicillin-resistant S. aureus (MRSA) isolates (Health Canada, 2010). In
addition, telavancin was granted approval in Europe for the treatment
of adult patients with HABP/VABP caused by susceptible isolates of
MRSA when alternative treatments are not suitable (Clinigen Healthcare
Ltd., 2014). During clinical development and commercialization, telavancin
has demonstrated in vitro activity against S. aureus (including MRSA),
heterogeneous vancomycin-intermediate (hVISA) and vancomycin-
intermediate S. aureus (VISA), streptococci, and vancomycin-susceptible
enterococci (Karlowsky et al., 2011;Mendes et al., 2011, 2012a). Favorable
in vivo and clinical results have also been reported (Brinkman et al., 2012;
Crandon et al., 2010; Darouiche et al., 2009; Hegde et al., 2010; Joson et al.,1-319-665-3371.
s).
s is an open access article under2011; Kaushal and Hassoun, 2012; Reyes et al., 2006; Twilla et al., 2011;
Xiong et al., 2012).
Antimicrobial agents belonging to the lipoglycopeptide class possess the
propensity to adhere to plastic (Arhin et al., 2008; Rennie et al., 2007). Early
in 2014, a revised broth microdilution susceptibility testing methodology
for telavancin was approved by the Food and Drug Administration (FDA)
and published in a labeling supplement for VIBATIV® (telavancin) package
insert (Theravance Biopharma Antibiotics, Inc, 2014). This revisedmethod
was also published in the Clinical and Laboratory Standards Institute (CLSI)
M100-S24 document (CLSI, 2014). The new method provides improved
drug solubility (procedure for water-insoluble agents) during panel prepa-
ration and drug availability during susceptibility testing (polysorbate-
80 [P-80]), modiﬁcations deemed necessary for more accurate, precise,
and reproducible telavancinMIC determinations (Farrell et al., 2014). In
contrast to the initially established susceptibility testing method for
telavancin (CLSI, 2013), the use of P-80 in the revised method is consis-
tent with those applied for other glycopeptide agents (oritavancin and
dalbavancin) (Arhin et al., 2008; Rennie et al., 2007).
The telavancin potency and spectrum of activity have been annually
monitored against worldwide collections of clinical isolates through the
Telavancin International Surveillance Program for the Americas, Europe
andAsia-Paciﬁc (APAC) regions, as part of theFDApostmarketing studies
(Mendes et al., 2010, 2012b; Putnam et al., 2010). However, thesethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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testing method. Although the revised method for telavancin provides
more accurate MIC results, these are lower than those generated by the
previous method (Farrell et al., 2014). Therefore, the quality control
(QC) ranges and breakpoints for telavancin were also revised (Ross
et al., 2014; Theravance Biopharma Antibiotics, Inc, 2014). This study
was conducted to assess and update the activity of telavancin against a
contemporary (2013) worldwide collection of clinical isolates using the
recently approved broth microdilution method.
2. Materials and methods
2.1. Bacterial strains
A total of 12,346 consecutive, nonduplicate Gram-positive clinical
isolates were included in this study, which were collected from 90 cen-
ters in North America (2 countries, 29 centers), Latin America (4 coun-
tries, 10 centers), Europe (18 countries, 31 centers), and APAC regions
(8 countries, 20 centers). These isolates were recovered from bacter-
emia (2739; 22.2%); skin and skin structure infection (4243; 34.4%);
and from patients with community-acquired pneumonia (1401; 11.3%)
and HABP/VABP (1821; 14.7%), urinary tract infections (458; 3.7%),
intra-abdominal infections (419; 3.4%), and other less prevalent or un-
determined infection sources (1265; 10.2%). Isolates were determined
to be clinically signiﬁcant based on local guidelines and submitted to a
central monitoring laboratory (JMI Laboratories, North Liberty, IA,
USA), as part of the SENTRY Antimicrobial Surveillance Program for
2013. Isolates were initially identiﬁed by the participating laboratory
and bacterial identiﬁcations conﬁrmed by the reference monitoring
laboratory by standard algorithms and supported by Matrix Assisted
Laser Desorption Ionization Time-of-Flight Mass Spectrometry (Bruker
Daltonics, Bremen, Germany).
2.2. Antimicrobial susceptibility testing
Isolates were tested for susceptibility by brothmicrodilution following
guidelines in the CLSI M07-A9 document (CLSI, 2012). Testing was per-
formed using dry-form panels manufactured by Thermo Fisher Scientiﬁc
(Cleveland, OH, USA). These panels were previously validated and
shown to provide MIC results equivalent to the revised and FDA-
approved broth microdilution method described above (Farrell et al.,
2014). Quality assurance was performed by concurrent testing of CLSI-
recommended QC reference strains (S. aureus ATCC 29213, EnterococcusTable 1
Antimicrobial activity and MIC distribution for telavancin when tested against contemporary
susceptibility testing method.
Organism (no. tested) MIC (μg/mL) Number (cumulative %) inhibited at te
50% 90% ≤0.015 0.03 0.06
S. aureus (6843) 0.03 0.06 324 (4.7) 4741 (74.0) 1770 (9
MSSA (4230) 0.03 0.06 241 (5.7) 2931 (75.0) 1056 (N
MRSA (2613) 0.03 0.06 83 (3.2) 1810 (72.4) 714 (9
CoNS (875) 0.03 0.06 153 (17.5) 310 (52.9) 397 (9
E. faecalis (702) 0.12 0.12 2 (0.3) 20 (3.1) 228 (3
E. faecium (437) 0.03 2 156 (35.7) 72 (52.2) 9 (5
Vancomycin-susceptible (228) ≤0.015 0.03 149 (65.4) 70 (96.1) 8 (9
VanA (196) 1 2 0 (0.0) 0 (0.0) 0 (0
VanB (13) ≤0.015 0.25 7 (53.8) 2 (69.2) 1 (7
S. pneumoniae (1878) ≤0.015 ≤0.015 1867 (99.4) 11 (100.0)
VGS (522) ≤0.015 0.03 332 (63.6) 178 (97.7) 12 (1
S. anginosus group (176) ≤0.015 0.03 111 (63.1) 62 (98.3) 3 (1
BHS (1057) ≤0.015 0.03 684 (64.7) 333 (96.2) 36 (9
S. pyogenes (478) ≤0.015 0.03 416 (87.0) 41 (95.6) 20 (9
S. agalactiae (438) 0.03 0.03 139 (31.7) 283 (96.3) 13 (9
S. dysgalactiae (140) ≤0.015 ≤0.015 128 (91.4) 9 (97.9) 3 (1
VanA = vancomycin and teicoplanin MIC values of N4 and N8 μg/mL, respectively; VanB = va
a Modal MIC values are shown in bold.
b All VanA phenotype.faecalis ATCC 29212, and Streptococcus pneumoniae ATCC 49619) (CLSI,
2014). All QC results were within published acceptable ranges. The
telavancin FDA (and European Committee on Antimicrobial Susceptibility
Testing [EUCAST, forMRSA only])–approved breakpoints for susceptibility
are as follows: S. aureus,≤0.12 μg/mL; Streptococcus anginosus group (also
applied for viridans group streptococci [VGS]),≤0.06 μg/mL; Streptococcus
pyogenes and Streptococcus agalactiae (also applied for the β-hemolytic
streptococci [BHS] group), ≤0.12 μg/mL (EUCAST, 2014; Theravance
Biopharma Antibiotics, Inc, 2014). Breakpoint criteria for comparator
agents were those from CLSI and EUCAST (CLSI, 2014; EUCAST, 2014).
3. Results and discussions
Overall, telavancin had MIC50 and MIC90 values of 0.03 and
0.06 μg/mL against S. aureus, respectively, regardless of methicillin sus-
ceptibility, and inhibited all isolates at the revised FDA breakpoint for
susceptibility (≤0.12 μg/mL; Table 1). When data analysis was per-
formed according to geographic region, S. aureus collected from the
Americas and Europe showed telavancin MIC50 values of 0.03 μg/mL
(59.5–81.1% of isolates inhibited at ≤0.03 μg/mL), while S. aureus col-
lected from the APAC region displayed a MIC50 value of 0.06 μg/mL
(41.1% of isolates inhibited at ≤0.03 μg/mL; Fig. 1). In addition, isolates
from the Americas and Europe exhibiting vancomycin MIC results of
0.5–1 μg/mL had telavancin modal MIC values of 0.03 μg/mL, whereas
thosewith vancomycin results of 2 μg/mL (breakpoint for susceptibility)
had a telavancin modal MIC value of 0.06 μg/mL (Fig. 1). S. aureus from
the APAC region with vancomycin MIC values of 0.5 μg/mL and
1–2 μg/mL had telavancin modalMIC results of 0.03 and 0.06 μg/mL, re-
spectively (Fig. 1). Eight S. aureus showing highest telavancin MIC re-
sults (i.e., 0.12 μg/mL) had vancomycinMIC values of 1–2 μg/mL (Fig. 1).
When tested against MRSA isolates, telavancin exhibited similar ac-
tivity (MIC50/90, 0.03/0.06 μg/mL) against North American (81.2%
inhibited at ≤0.03 μg/mL) and European (76.0% inhibited at
≤0.03 μg/mL) isolates. Slightly higher MIC50 values (MIC50/90, 0.06/
0.06 μg/mL) were noted against MRSA from Latin America (40.9%
inhibited at ≤0.03 μg/mL) and APAC (32.7% inhibited at ≤0.03 μg/mL;
data not shown). With these MIC50 and MIC90 values obtained against
MRSA, telavancin (MIC50/90, 0.03/0.06 μg/mL) was 8-fold more potent
than daptomycin (MIC50/90, 0.25/0.5 μg/mL) and 16- to 32-fold more
active than vancomycin (MIC50/90, 1/1 μg/mL) and linezolid (MIC50/90,
1/1 μg/mL; Table 2). Tetracycline (MIC50/90, 0.12/2 μg/mL; 90.0–90.9%
susceptible) and trimethoprim-sulfamethoxazole (MIC50/90, ≤0.5/
≤0.5 μg/mL; 97.4% susceptible) were also active against MRSA (Table 2).(2013) worldwide collection of clinical isolates using a recently revised and approved
lavancin MIC (μg/mL)a




8.3) 13 (99.8) 2 (100.0)
5.6) 431 (97.0) 10 (98.4) 1 (98.6) 0 (98.6) 2b (98.9) 8b (100.0)
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ncomycin and teicoplanin MIC values of N4 and ≤8 μg/mL, respectively.
Fig. 1. Scatter diagram of telavancin MIC values plotted against the vancomycin MIC values
for 6843 S. aureus strains from North America (A), Europe (B), Latin America (C), and Asia-
Paciﬁc (D) regions. The darker vertical and horizontal lines represent the telavancin
(≤0.12 μg/mL) and vancomycin (≤2 μg/mL) breakpoints for susceptibility against S. aureus
according to the FDA/EUCAST and EUCAST/CLSI, respectively. Telavancin modal MIC results
against isolates displaying vancomycin MIC values of 0.25, 0.5, 1, or 2 μg/mL are bolded.
The telavancinMIC50 andMIC90 results are underlined (double line when results coincide).
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0.03 and 0.06 μg/mL, respectively, were consistent across all sampled
coagulase-negative staphylococci (CoNS), regardless of region or oxacil-
lin susceptibility (Tables 1 and 2). Telavancin (MIC50/90, 0.03/0.06 μg/mL)
was 8- to 16-fold more potent than daptomycin (MIC50/90, 0.25/
0.5 μg/mL) and linezolid (MIC50/90, 0.5/1 μg/mL) and 32-foldmore active
than vancomycin (MIC50/90, 1/2 μg/mL) against the entire population of
CoNS (Table 2). Other antimicrobial agents tested against CoNS showed
reduced coverage (MIC90, N2 μg/mL; 13.5–78.3% resistant; Table 2).
Overall, E. faecalis isolates were very susceptible to telavancin
(MIC50/90, 0.12/0.12 μg/mL), and 98.4% of all isolates or N99.9% ofvancomycin-susceptible isolates were inhibited at the FDA breakpoint
for susceptibility (i.e. ≤0.25 μg/mL; Table 1). All E. faecalis displaying
telavancin MIC values of ≥2 μg/mL had a VanA resistance phenotype.
A comparative data analysis based on MIC90 values demonstrated
that telavancin (MIC50/90, 0.12/0.12 μg/mL) was 8- to 16-fold more
potent than vancomycin (MIC50/90, 1/2 μg/mL), daptomycin (MIC50/90,
1/1 μg/mL), linezolid (MIC50/90, 1/1 μg/mL), and ampicillin (MIC50/90,
1/2 μg/mL) when tested against vancomycin-susceptible E. faecalis
(Table 2). Vancomycin-susceptible E. faecium (MIC50/90, ≤0.015/
0.03 μg/mL) had telavancin MIC values lower than vancomycin-
susceptible E. faecalis (MIC50/90, 0.12/0.12 μg/mL; Table 1). In addition,
telavancin was active against vancomycin-resistant (VanB phenotype)
E. faecium (MIC50/90, ≤0.015/0.25 μg/mL), while higher MIC results were
obtained against VanA-phenotype strains (MIC50/90, 1/2 μg/mL; Table 1).
Streptococci exhibited low MIC results for telavancin, with MIC50
and modal MIC values of ≤0.015 μg/mL, except for S. agalactiae
(0.03 μg/mL for both; Tables 1 and 2). Overall, telavancin (MIC50/90,
≤0.015/≤0.015 μg/mL), vancomycin (MIC50/90, 0.25/0.5 μg/mL), and li-
nezolid (MIC50/90, 0.12/0.25 μg/mL) were most potent against
S. pneumoniae, while telavancin (MIC50/90, ≤0.015/0.03 μg/mL) and
penicillin (MIC50/90, ≤0.06/0.5 μg/mL) were most potent against VGS.
However, marginal susceptibility rates (77.0–84.9%) were observed
for penicillin against VGS, whereas vancomycin, daptomycin, and line-
zolid (MIC50/90, 0.25–05/1 μg/mL) had greater susceptibility values
(99.2–100.0% susceptible). Telavancin still had MIC90 results at least
16-fold lower than the comparators against S. pneumoniae or VGS
(Table 2). When tested against BHS, telavancin (MIC50/90, ≤0.015/
0.03 μg/mL) and penicillin (MIC50/90,≤0.06/≤0.06 μg/mL) showed simi-
larly potent MIC50 and MIC90 results, which were followed by those
obtained for daptomycin (MIC50/90,≤0.06/0.25 μg/mL) and vancomycin
(MIC50/90, 0.25/0.5 μg/mL).
This study provides a reassessment of telavancin activity against a
worldwide collection of clinical Gram-positive isolates using a revised
and FDA-approved brothmicrodilution testingmethod and appropriate
interpretive breakpoints. In summary, potent in vitro activity was ob-
tained for telavancin against S. aureus, inhibiting all isolates at the FDA
breakpoint for susceptibility. Some variations in the MIC50 values
(0.03–0.06 μg/mL) were obtained for telavancin against S. aureus and
the MRSA subset according to geographic region, albeit the number of
sampled isolates from APAC was smaller than those from other areas.
VISA isolates were not present in this sampling; therefore, the
telavancin in vitro activity could not be assessed against these isolates.
Potent telavancin MIC results were also obtained against streptococci
and vancomycin-susceptible enterococci, while higher MIC values
were noted against the VanA resistance phenotype. Overall, these
MIC50 and MIC90 results were more active than comparator agents
when tested against selected species or groups of isolates, except for
BHS, against which telavancin and penicillin showed similar poten-
cies. These results benchmark the telavancin spectrum and activity
when applying the recently revised and approved broth microdilution
testing method.Conﬂict of interest
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Table 2
Antimicrobial activity of telavancin and comparator agents when tested against contemporary (2013) worldwide collection of clinical isolates.
Organism (number tested) MIC (μg/mL) % Susceptible/% intermediate/% resistanta
Antimicrobial agent Range 50% 90% FDA CLSI EUCAST
MRSA (2,613)
Telavancin ≤0.015 to 0.12 0.03 0.06 100.0/-b/- -/-/- 100.0/-/-
Vancomycin 0.25–2 1 1 100.0/0.0/0.0 100.0/0.0/0.0
Daptomycin ≤0.06 to 1 0.25 0.5 100.0/-/- 100.0/0.0/0.0
Linezolid ≤0.12 to N8 1 1 99.9/0.0/0.1 99.9/0.0/0.1
Levoﬂoxacin ≤0.12 to N4 4 N4 28.2/1.3/70.5 28.2/1.3/70.5
Erythromycin ≤0.12 to N16 N16 N16 17.6/2.5/79.9 17.8/0.7/81.5
Clindamycin ≤0.25 to N2 ≤0.25 N2 66.6/0.1/33.3 66.3/0.3/33.4
Gentamicin ≤1 to N8 ≤1 N8 88.9/0.3/10.8 88.2/0.0/11.8
Tetracycline 0.06 to N32 0.12 2 90.9/0.4/8.7 90.0/0.5/9.5
Trimethoprim-sulfamethoxazole ≤0.5 to N4 ≤0.5 ≤0.5 97.4/0.0/2.6 97.4/0.1/2.5
CoNS (875)
Telavancin ≤0.015 to 0.25 0.03 0.06 -/-/- -/-/- -/-/-
Oxacillin ≤0.25 to N2 N2 N2 21.7/0.0/78.3 21.7/0.0/78.3
Vancomycin ≤0.12 to 2 1 2 100.0/0.0/0.0 100.0/0.0/0.0
Daptomycin ≤0.06 to 4 0.25 0.5 99.8/-/- 99.8/0.0/0.2
Linezolid 0.25 to N8 0.5 1 99.7/0.0/0.3 99.7/0.0/0.3
Levoﬂoxacin ≤0.12 to N4 0.5 N4 52.8/2.4/44.8 52.8/2.4/44.8
Erythromycin ≤0.12 to N16 N16 N16 35.9/0.9/63.2 35.9/0.6/63.5
Clindamycin ≤0.25 to N2 ≤0.25 N2 66.5/1.2/32.3 65.7/0.8/33.5
Gentamicin ≤1 to N8 ≤1 N8 61.8/6.7/31.5 57.9/0.0/42.1
Tetracycline ≤0.03 to N32 0.5 32 85.0/1.5/13.5 80.8/3.2/16.0
Trimethoprim-sulfamethoxazole ≤0.5 to N4 ≤0.5 N4 63.7/0.0/36.3 63.7/18.0/18.3
E. faecalis (702)
Telavancin ≤0.015 to N2 0.12 0.12 98.4c/-/- -/-/- -/-/-
Ampicillin ≤0.25 to 4 1 2 100.0/0.0/0.0 100.0/0.0/0.0
Vancomycin 0.5 to N16 1 2 98.4/0.2/1.4 98.4/0.0/1.6
Daptomycin ≤0.06 to 4 1 1 100.0/-/- -/-/-
Linezolid 0.25–2 1 1 100.0/0.0/0.0 100.0/0.0/0.0
Levoﬂoxacin 0.25 to N4 1 N4 73.5/0.6/25.9 74.1/0.0/25.9
Tetracycline 0.06 to N32 N32 N32 21.5/0.8/77.7 -/-/-
Vancomycin-susceptible E. faecium (228)
Telavancin ≤0.015 to 0.12 ≤0.015 0.03 -/-/- -/-/- -/-/-
Ampicillin ≤0.25 to N8 N8 N8 11.0/0.0/89.0 9.6/1.4/89.0
Vancomycin 0.5–4 1 1 100.0/0.0/0.0 100.0/0.0/0.0
Daptomycin ≤0.06 to 4 2 2 100.0/-/- -/-/-
Linezolid 0.5–2 1 1 100.0/0.0/0.0 100.0/0.0/0.0
Levoﬂoxacin 1 to N4 N4 N4 10.5/4.0/85.5 14.5/0.0/85.5
Tetracycline 0.12 to N32 0.5 N32 52.9/0.8/46.3 -/-/-
S. pneumoniae (1878)
Telavancin ≤0.015 to 0.03 ≤0.015 ≤0.015 -/-/- -/-/- -/-/-
Penicillin ≤0.06 to 8 ≤0.06 2 90.9/8.2/0.9d -/-/-
Penicillin ≤0.06 to 8 ≤0.06 2 60.5/21.0/18.5e 60.5/30.4/9.1
Vancomycin ≤0.12 to 0.5 0.25 0.5 100.0/-/- 100.0/0.0/0.0
Linezolid ≤0.06 to 1 0.12 0.25 -/-/- -/-/-
Levoﬂoxacin ≤0.12 to 2 1 1 100.0/-/- 100.0/0.0/0.0
Erythromycin 0.25 to N4 1 1 98.9/0.2/0.9 98.9/0.0/1.1
Clindamycin ≤0.12 to N16 ≤0.12 N16 57.8/0.8/41.4 57.8/0.8/41.4
Tetracycline ≤0.25 to N2 ≤0.25 N2 75.3/0.4/24.3 75.7/0.0/24.3
VGS (522)
Telavancin ≤0.015 to 0.06 ≤0.015 0.03 100.0/-/- -/-/- -/-/-
Penicillin ≤0.06 to N8 ≤0.06 0.5 77.0/19.7/3.3 84.9/11.8/3.3
Vancomycin ≤0.12 to 1 0.5 1 100.0/-/- 100.0/0.0/0.0
Daptomycin ≤0.06 to 2 0.25 1 99.2/-/- -/-/-
Linezolid ≤0.12 to 4 0.5 1 99.8/-/- -/-/-
Levoﬂoxacin 0.25 to N4 1 2 96.3/0.6/3.1 -/-/-
Erythromycin ≤0.12 to N16 ≤0.12 16 58.7/2.7/38.6 -/-/-
Clindamycin ≤0.25 to N2 ≤0.25 N2 87.1/1.0/11.9 88.1/0.0/11.9
Tetracycline ≤0.03 to N32 0.5 N32 67.4/3.1/29.5 -/-/-
BHS (1057)
Telavancin ≤0.015 to 0.12 ≤0.015 0.03 100.0/-/- -/-/- -/-/-
Penicillin ≤0.06 to 0.12 ≤0.06 ≤0.06 100.0/-/- 100.0/0.0/0.0
Vancomycin ≤0.12 to 0.5 0.25 0.5 100.0/-/- 100.0/0.0/0.0
Daptomycin ≤0.06 to 1 ≤0.06 0.25 100.0/-/- 100.0/0.0/0.0
Linezolid ≤0.12 to 1 1 1 100.0/-/- 100.0/0.0/0.0
Levoﬂoxacin ≤0.12 to N4 0.5 1 99.3/0.2/0.5 95.4/3.9/0.7
Erythromycin ≤0.12 to N16 ≤0.12 N16 72.6/1.1/26.3 72.6/1.1/26.3
Clindamycin ≤0.25 to N2 ≤0.25 N2 85.7/0.4/13.9 86.1/0.0/13.9
Tetracycline 0.06 to N32 1 N32 51.3/1.9/46.8 50.2/1.1/48.7
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